Novo Nordisk Logo - Search News

Novo Nordisk Shares Fall

Barron's on MSN · 9h

Novo Nordisk Is Falling. Compeitition Is a Killer.

Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.

Reuters on MSN · 2d

Novo Nordisk trial with next-gen diabetes drug shows 15.7% weight loss but shares fall

Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 diabetes cut their weight by 15.7% after 68 weeks, but shares fell, likely on the lower-than-expected weight loss.

Business Insider · 2d

Novo Nordisk down 6% after results for trial of weight-loss drug CagriSema

Shares of Novo Nordisk (NVO) trading in New York are down $5.22, or 6%, to $81.95 in the pre-market session.Discover the Best Stocks and

6don MSN

'For Novo Nordisk, I do not worry a lot about tariffs:' CEO Lars Jørgensen

Novo Nordisk (NVO) is not concerned by the ongoing US trade war and the 25% tariff set to go into effect for pharmaceutical ...

1d

Novo Nordisk (0QIU) Receives a Buy from Goldman Sachs

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK890.00.

Investor's Business Daily on MSN2d

Novo Nordisk Dives 9%. Why Eli Lilly Now Has The Upper Hand.

Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results